Health Care Analysis 25 (1):1-20 (2017)
AbstractThis article is about the justifiability of accepting worse cost effectiveness for orphan drugs, that is, treatments for rare diseases, in a publicly financed health care system. Recently, three arguments have been presented that may be used in favour of exceptionally advantageous economic terms for orphan drugs. These arguments share the common feature of all referring to considerations of justice or fairness: the argument of the irrelevance of group size, the argument from the principle of need, and the argument of identifiability. It is argued that all of these arguments fail to support the conclusion that orphan drugs should be subsidized to a larger extent than treatments for common diseases. The argument of the irrelevance fails to distinguish between directly and indirectly relevant considerations of fairness or justice. The recent attempt to revive the moral relevance of identifiability has provided no novel reasons to think that identifiability is morally relevant in itself or due to considerations of fairness and justice. The argument from the principle of need does not fail due to any inherent flaw in the principle as such. Rather, this principle can be interpreted in different ways, and none of these interpretations support exceptionally advantageous terms economically for treating rare diseases specifically. It is concluded that we are awaiting justice based reasons for the preferential treatment of orphan drugs.
Similar books and articles
Ethical and Social Aspects on Rare Diseases.Dusanka Krajnovic - 2012 - Filozofija I Društvo 23 (4):32-48.
A Fair Share for the Orphans: Ethical Guidelines for a Fair Distribution of Resources Within the Bounds of the 10-Year-Old European Orphan Drug Regulation: Figure 1.Wim Pinxten, Yvonne Denier, Marc Dooms, Jean-Jacques Cassiman & Kris Dierickx - 2012 - Journal of Medical Ethics 38 (3):148-153.
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights From the US and the EU Biopharmaceutical Industry. [REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.
Ethical Issues in Funding Orphan Drug Research and Development.C. A. Gericke - 2005 - Journal of Medical Ethics 31 (3):164-168.
Paying a High Price for Low Costs: Why There Should Be No Legal Constraints on the Profits That Can Be Made on Drugs for Tropical Diseases.J. Sonderholm - 2009 - Journal of Medical Ethics 35 (5):315-319.
Extraordinary Pricing of Orphan Drugs: Is It a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? [REVIEW]Thomas A. Hemphill - 2010 - Journal of Business Ethics 94 (2):225 - 242.
Pharmacogenetic Interventions, Orphan Drugs, and Distributive Justice: The Role of Cost-Benefit Analysis.Arti K. Rai - 2002 - Social Philosophy and Policy 19 (2):246-270.
How to Improve Specific Databases for Clinical Data in Rare Diseases? The Example of Hereditary Haemorrhagic Telangiectasia.Evelyne Decullier, Sophie Dupuis-Girod, Henri Plauchu, Jacques Perret & François Chapuis - 2012 - Journal of Evaluation in Clinical Practice 18 (3):523-527.
The Use of Cost-Effectiveness by the National Institute for Health and Clinical Excellence (NICE): No(T yet an) Exemplar of a Deliberative Process.M. Schlander - 2008 - Journal of Medical Ethics 34 (7):534-539.
Ethical Issues Related to the Access to Orphan Drugs in Brazil: The Case of Mucopolysaccharidosis Type I.Raquel Boy, Ida V. D. Schwartz, Bárbara C. Krug, Luiz C. Santana-da-Silva, Carlos E. Steiner, Angelina X. Acosta, Erlane M. Ribeiro, Marcial F. Galera, Paulo G. C. Leivas & Marlene Braz - 2011 - Journal of Medical Ethics 37 (4):233-239.
Ethical and Economic Considerations of Rare Diseases in Ethnic Minorities: The Case of Mucopolysaccharidosis VI in Colombia.Diego Rosselli, Juan-David Rueda & Martha Solano - 2012 - Journal of Medical Ethics 38 (11):699-700.
Ethical Issues in Funding Research and Development of Drugs for Neglected Tropical Diseases.L. Oprea, A. Braunack-Mayer & C. A. Gericke - 2009 - Journal of Medical Ethics 35 (5):310-314.
Effective Use of a Limited Antiviral Stockpile for Pandemic Influenza.Nimalan Arinaminpathy, J. Savulescu & Angela R. Mclean - 2009 - Journal of Bioethical Inquiry 6 (2):171-179.
Added to PP
Historical graph of downloads
Citations of this work
The Normative Significance of Identifiability.Tomasz Żuradzki - 2019 - Ethics and Information Technology 21 (4):295-305.
Sustainability Principle for the Ethics of Healthcare Resource Allocation.Christian Munthe, Davide Fumagalli & Erik Malmqvist - 2021 - Journal of Medical Ethics 47 (2):90-97.
Principles of Need and the Aggregation Thesis.Erik Gustavsson & Niklas Juth - 2019 - Health Care Analysis 27 (2):77-92.
Rare Diseases in Healthcare Priority Setting: Should Rarity Matter?Andreas Albertsen - 2022 - Journal of Medical Ethics 48 (9):624-628.
Natural and Social Inequality.David Wasserman & Sean Aas - 2016 - Journal of Moral Philosophy 13 (5):576-601.